Damon Dierker
Optometrist · Indianapolis, INNPI 1063453819
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. It is spread thinly across 47 manufacturers, the largest accounting for just 14.4%. Among optometrist clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,281 payments — averaging $551.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$102K
- AbbVie$85K
- Bausch & Lomb Americas Inc.$85K
- Oyster Point Pharma, Inc.$84K
- Sun Pharmaceutical Industries Inc.$79K
- Alcon$65K
- plus $207K from 41 others
Across 94 payments — averaging $1267.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$102K
- AbbVie$8K
- Oyster Point Pharma, Inc.$6K
- Notal Vision, Inc.$3K
What the payments were for
- Consulting fees$246,96935%
- Speaking & faculty fees$380,81454%
- Travel & lodging$34,9725%
- Food & beverage$43,9306%
- Education$570%
- Gifts$170%
- Entertainment$1560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYRVAYA$82,220
- CEQUA$77,761
- MIEBO$74,547
- XIIDRA$69,137
- XDEMVY$41,329
- VUITY$35,361
- TEARCARE SYSTEM$34,696
- EYSUVIS$31,936
- ILUX$26,580
- TRYPTYR$25,884
- TearCare$22,674
- TearCare SmartLid$21,460
- TEARCARE(TM) (2.2) SYSTEM KIT$21,460
- AdaptDx$18,638
- OMNI(R) SURGICAL SYSTEM (US)$13,820
- TearLab Osmolarity System$13,154
- RESTASIS MULTIDOSE$12,365
- RESTASIS$11,648
- Prokera$10,082
- Oxervate$9,372
How this compares
$706,915 in reported general payments places this provider in the 95th percentile of 1,318 optometrist providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 35 | $1,580,290 |
| RestasisCyclosporine | 229 | $310,105 |
| XiidraLifitegrast | 173 | $215,858 |
| CequaCyclosporine | 136 | $116,919 |
| XdemvyLotilaner | 62 | $115,422 |
| LumiganBimatoprost | 126 | $71,906 |
| TyrvayaVarenicline Tartrate | 82 | $68,075 |
| CombiganBrimonidine Tartrate/Timolol | 55 | $23,186 |
| MieboPerfluorohexyloctane/Pf | 21 | $17,464 |
| VevyeCyclosporine | 15 | $14,154 |
| RocklatanNetarsudil Mesylat/Latanoprost | 31 | $13,327 |
| EysuvisLoteprednol Etabonate | 19 | $11,476 |
| Cyclosporine | 35 | $11,018 |
| RhopressaNetarsudil Mesylate | 17 | $8,752 |
| VyzultaLatanoprostene Bunod | 15 | $5,681 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $9,689 | $1,580,29035 claims |
| AbbVieRestasis, Lumigan, Combigan | $85,359 | $405,198410 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $84,674 | $239,003209 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $79,085 | $116,919136 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $53,205 | $115,42262 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $84,091 | $68,07582 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $862 | $22,07948 claims |
| Harrow Eye, LLCVevye | $437 | $14,15415 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $29,493 | $11,47619 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm | $632 | $4,54818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,318 optometrist providers in Indiana.
Other optometrist in Indianapolis
- Rhonda RobinsonIndianapolis$205K
- Brenda WahlIndianapolis$38K
- Peter KoernerIndianapolis$11K
- Jessica HultsIndianapolis$10K
- Branden ShafferIndianapolis$9K
- Scott AllisonIndianapolis$8K
- Alma NoreikaIndianapolis$7K
- Scott HastyIndianapolis$7K
- Diana FisherIndianapolis$7K
- Nathan MorrowIndianapolis$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.